Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.02Last Year’s EPS
-0.25Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: 15.94%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and development progress, particularly with ARCALYST and the new KPL-387 program. However, the call also noted some challenges, including a net loss for the year and the discontinuation of abiprubart development. Despite these challenges, the company's strong financial position and future growth prospects offer a positive outlook.Company Guidance
During Kiniksa Pharmaceuticals' fourth-quarter 2024 earnings call, the company provided guidance for ARCALYST's 2025 revenue, projecting net revenue between $560 million and $580 million. The call highlighted significant financial metrics, including a 79% increase in ARCALYST's full-year 2024 revenue to $417 million, and a 108% rise in collaboration profit to $234.7 million for the same period. Kiniksa also announced the advancement of KPL-387, a monoclonal antibody IL-1 receptor antagonist, with plans to initiate a Phase 2/3 trial in mid-2025 and target market entry by the 2028/2029 timeframe. The company's robust financial position was underscored by a $244 million cash balance at the end of 2024 and an expectation to remain cash flow positive annually.Strong ARCALYST Revenue Growth
ARCALYST product revenue grew 72% to $122.5 million in the fourth quarter and 79% to $417 million for the full year 2024.
Launch of KPL-387 Development Program
KPL-387 is an independently developed monoclonal antibody IL-1 receptor antagonist with potential for monthly Sub-Q dosing in recurrent pericarditis. Phase 2/3 trial expected to start mid-2025.
Positive Financial Position
Ended 2024 with a $244 million cash balance and expect to remain cash flow positive on an annual basis.
Collaboration Profit Growth
ARCALYST collaboration profit grew 125% to $76.3 million in the fourth quarter and 108% to $234.7 million for the full year 2024.
2025 ARCALYST Revenue Guidance
Forecasted net revenue for ARCALYST is between $560 million and $580 million for 2025.
---
KNSA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KNSA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $19.63 | $19.72 | +0.46% |
| Oct 29, 2024 | $27.59 | $23.26 | -15.69% |
| Jul 23, 2024 | $26.29 | $25.20 | -4.15% |
| Apr 23, 2024 | $17.10 | $17.68 | +3.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Kiniksa Pharmaceuticals (KNSA) report earnings?
Kiniksa Pharmaceuticals (KNSA) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is Kiniksa Pharmaceuticals (KNSA) earnings time?
Kiniksa Pharmaceuticals (KNSA) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KNSA EPS forecast?
KNSA EPS forecast for the fiscal quarter 2025 (Q1) is 0.02.
---